Breaking News

SGS To Open New GMP/GLP Lab in CA

By Kristin Brooks | January 15, 2014

Will provide microbiological testing and bioanalytical services

SGS is investing in a fifth North American Life Science Services lab in Carson, CA. The 8,000-sq.-ft. Life Science Services GMP/GLP lab will provide microbiological testing and bioanalytical services. The new facility will include 6,000 sq. ft. of dedicated lab space and 2,000 sq. ft. of office space. The facility is projected to open 3Q14 and will initially employ seven scientific staff, with room to expand.
 
“We are very pleased to undertake this project because it allows SGS to establish a West Coast, Life Science Services presence to address the California pharmaceutical and biotechnology market,” said Jeff McDonald, chief operating officer, SGS North America.
 
“This development permits SGS to leverage the bioanalytical testing expertise from the laboratory in Poitiers, France, where SGS has more than 700 validated bioanalytical assays to date,” added Anne Hays, executive vice president, Life Science Services.
 
SGS has 20 labs offering contract analytical and bioanalytical services and is present in North America, Europe, and Asia. SGS also provides clinical trial management (Phase I to IV) and services encompassing data management and statistics, PK/PD modeling and simulation, pharmacovigilance and regulatory consultancy.
blog comments powered by Disqus
  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • A Case for One Assay Analysis of PK and Immunogenicity in Biosimilar Research

    A Case for One Assay Analysis of PK and Immunogenicity in Biosimilar Research

    Stephanie Mowery, Sherri Rinker, Franklin Spriggs and Bo Kowalcyk , AIT Bioscience||June 2, 2015
    Moving forward clinical studies will have to include a comparative assessment of pharmacokinetics and immunogenicity to the original reference biologic drug